| Authors: |
Marijic P; GSK, Munich, Germany. pavo.x.marijic@gsk.com., Jamróz-Dolińska K; Clever-Access, Kraków, Poland., Margas W; Clever-Access, Kraków, Poland., Gaianu L; GSK, London, UK., Mathur G; GSK, Rockville, MD, USA., Wojciechowski P; Clever-Access, Kraków, Poland., Pinto T; GSK, Wavre, Belgium., Vincent T; GSK, London, UK., Petousis-Harris H; University of Auckland, Auckland, New Zealand., Nolan T; University of Melbourne, Melbourne, VIC, Australia., Martinón-Torres F; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Spain.; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain., Harrison LH; Center for Genomic Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Kocaata Z; GSK, Munich, Germany. |
